NCT05925491View on ClinicalTrials.gov

Pembrolizumab in Locally Advanced Sinonasal Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

December 24, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Sinonasal Undifferentiated Carcinoma
Interventions
DRUG

Pembrolizumab

Pembrolizumab administration in combination with chemotherapy for 3 cycles, followed by standard of care

DRUG

Cisplatin

Cisplatin 75mg/mq in combination with pembrolizumab 200 mg and docetaxel 75 mg/mq every three weeks (Q3W) for 3 courses.

DRUG

Docetaxel

Docetaxel 75 mg/mq in combination with pembrolizumab 200 mg and cisplatin 75 mg/mq every three weeks (Q3W) for 3 courses.

DRUG

Carboplatin

Carboplatin AUC 5 alternative to Cisplatin if toxicities occur.

Trial Locations (1)

27100

RECRUITING

Istituti Clinici Scientifici Maugeri, Pavia

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Istituti Clinici Scientifici Maugeri SpA

OTHER